Zhou X Y, Kitzis M D, Acar J F, Gutmann L
Laboratoire de Microbiologie Médicale, Université Paris VI, France.
J Antimicrob Chemother. 1993 Apr;31(4):473-80. doi: 10.1093/jac/31.4.473.
BRL 42715, a novel beta-lactamase inhibitor, was evaluated for its capacity to inhibit cephalosporinases. BRL 42715 was effective in potentiating the activity of antibiotics against clinical isolates of Enterobacteriaceae that produced high levels of cephalosporinases. This correlated well with the very low 50% inhibition values (< 0.004 mg/L) of BRL 42715 for cephalosporinases extracted from different species. When compared in vitro to clavulanic acid, sulbactam, and tazobactam, BRL 42715 was the most efficient inhibitor of cephalosporinase.
新型β-内酰胺酶抑制剂BRL 42715对其抑制头孢菌素酶的能力进行了评估。BRL 42715能有效增强抗生素对产生高水平头孢菌素酶的肠杆菌科临床分离株的活性。这与BRL 42715对从不同物种中提取的头孢菌素酶的极低50%抑制值(<0.004 mg/L)密切相关。在体外与克拉维酸、舒巴坦和他唑巴坦相比,BRL 42715是最有效的头孢菌素酶抑制剂。